Global Radioimmunotherapy Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Radioimmunotherapy market size will reach 2,903.82 Million USD in 2025 and is projected to reach 7,528.90 Million USD by 2032, with a CAGR of 14.58% (2025-2032). Notably, the China Radioimmunotherapy market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Radioimmunotherapy (RIT) is a specialized cancer treatment that harnesses the specificity of monoclonal antibodies and the cytotoxic power of radiation. It involves attaching radioactive isotopes to monoclonal antibodies, which are proteins designed to selectively target antigens found on cancer cells. Once administered into the patient's bloodstream, these antibodies seek out and bind to the cancer cells, delivering radiation directly to the tumor sites. The emitted radiation damages the cancer cells' DNA, leading to their destruction or death. Radioimmunotherapy offers the advantage of precise targeting, minimizing harm to surrounding healthy tissues compared to traditional radiation therapy and chemotherapy. It is particularly effective against certain types of blood cancers like lymphoma and leukemia, and ongoing research aims to expand its application to other types of solid tumors, offering promising therapeutic options for cancer patients.
The major global suppliers of Radioimmunotherapy include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, Nordic Nanovector, Philogen, RadioMedix, Telix Pharmaceuticals, Orano Med, Actinium Pharmaceuticals, Y-mAbs Therapeutics, Fusion Pharmaceuticals, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Radioimmunotherapy. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Radioimmunotherapy market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Radioimmunotherapy market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Radioimmunotherapy industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Radioimmunotherapy Include:
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Radioimmunotherapy Product Segment Include:
Beta-emitting
Targeted Alpha Therapy
Radioimmunotherapy Product Application Include:
Solid Tumor
Non Hodgkin Lymphoma
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Radioimmunotherapy Industry PESTEL Analysis
Chapter 3: Global Radioimmunotherapy Industry Porter's Five Forces Analysis
Chapter 4: Global Radioimmunotherapy Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Radioimmunotherapy Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Radioimmunotherapy Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Radioimmunotherapy Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Radioimmunotherapy market size will reach 2,903.82 Million USD in 2025 and is projected to reach 7,528.90 Million USD by 2032, with a CAGR of 14.58% (2025-2032). Notably, the China Radioimmunotherapy market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Radioimmunotherapy (RIT) is a specialized cancer treatment that harnesses the specificity of monoclonal antibodies and the cytotoxic power of radiation. It involves attaching radioactive isotopes to monoclonal antibodies, which are proteins designed to selectively target antigens found on cancer cells. Once administered into the patient's bloodstream, these antibodies seek out and bind to the cancer cells, delivering radiation directly to the tumor sites. The emitted radiation damages the cancer cells' DNA, leading to their destruction or death. Radioimmunotherapy offers the advantage of precise targeting, minimizing harm to surrounding healthy tissues compared to traditional radiation therapy and chemotherapy. It is particularly effective against certain types of blood cancers like lymphoma and leukemia, and ongoing research aims to expand its application to other types of solid tumors, offering promising therapeutic options for cancer patients.
The major global suppliers of Radioimmunotherapy include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, Nordic Nanovector, Philogen, RadioMedix, Telix Pharmaceuticals, Orano Med, Actinium Pharmaceuticals, Y-mAbs Therapeutics, Fusion Pharmaceuticals, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Radioimmunotherapy. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Radioimmunotherapy market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Radioimmunotherapy market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Radioimmunotherapy industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Radioimmunotherapy Include:
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Radioimmunotherapy Product Segment Include:
Beta-emitting
Targeted Alpha Therapy
Radioimmunotherapy Product Application Include:
Solid Tumor
Non Hodgkin Lymphoma
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Radioimmunotherapy Industry PESTEL Analysis
Chapter 3: Global Radioimmunotherapy Industry Porter's Five Forces Analysis
Chapter 4: Global Radioimmunotherapy Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Radioimmunotherapy Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Radioimmunotherapy Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Radioimmunotherapy Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Radioimmunotherapy Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Radioimmunotherapy Product by Type
- 1.2.1 Beta-emitting
- 1.2.2 Targeted Alpha Therapy
- 1.3 Radioimmunotherapy Product by Application
- 1.3.1 Solid Tumor
- 1.3.2 Non Hodgkin Lymphoma
- 1.4 Global Radioimmunotherapy Market Size Analysis (2020-2032)
- 1.5 Radioimmunotherapy Market Development Status and Trends
- 1.5.1 Radioimmunotherapy Industry Development Status Analysis
- 1.5.2 Radioimmunotherapy Industry Development Trends Analysis
- 2 Radioimmunotherapy Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Radioimmunotherapy Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Radioimmunotherapy Market Analysis by Country
- 4.1 Global Radioimmunotherapy Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Radioimmunotherapy Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Radioimmunotherapy Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.5 China Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.6 France Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.14 India Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Radioimmunotherapy Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Radioimmunotherapy Market Revenue by Key Suppliers (2021-2025)
- 5.2 Radioimmunotherapy Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Radioimmunotherapy Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Radioimmunotherapy Market Analysis by Type
- 6.1 Global Radioimmunotherapy Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Radioimmunotherapy Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Bayer
- 7.1.1 Bayer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Bayer Radioimmunotherapy Product Portfolio
- 7.1.3 Bayer Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Novartis
- 7.2.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Novartis Radioimmunotherapy Product Portfolio
- 7.2.3 Novartis Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Lantheus
- 7.3.1 Lantheus Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Lantheus Radioimmunotherapy Product Portfolio
- 7.3.3 Lantheus Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Aurobindo Pharma
- 7.4.1 Aurobindo Pharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Aurobindo Pharma Radioimmunotherapy Product Portfolio
- 7.4.3 Aurobindo Pharma Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Mundipharma
- 7.5.1 Mundipharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Mundipharma Radioimmunotherapy Product Portfolio
- 7.5.3 Mundipharma Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 China Isotope & Radiation
- 7.6.1 China Isotope & Radiation Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 China Isotope & Radiation Radioimmunotherapy Product Portfolio
- 7.6.3 China Isotope & Radiation Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 Curium Pharmaceuticals
- 7.7.1 Curium Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Curium Pharmaceuticals Radioimmunotherapy Product Portfolio
- 7.7.3 Curium Pharmaceuticals Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Gilead Sciences
- 7.8.1 Gilead Sciences Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Gilead Sciences Radioimmunotherapy Product Portfolio
- 7.8.3 Gilead Sciences Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 Clarity Pharmaceuticals
- 7.9.1 Clarity Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 Clarity Pharmaceuticals Radioimmunotherapy Product Portfolio
- 7.9.3 Clarity Pharmaceuticals Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Curasight
- 7.10.1 Curasight Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Curasight Radioimmunotherapy Product Portfolio
- 7.10.3 Curasight Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.11 Nordic Nanovector
- 7.11.1 Nordic Nanovector Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 Nordic Nanovector Radioimmunotherapy Product Portfolio
- 7.11.3 Nordic Nanovector Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.12 Philogen
- 7.12.1 Philogen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.12.2 Philogen Radioimmunotherapy Product Portfolio
- 7.12.3 Philogen Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.13 RadioMedix
- 7.13.1 RadioMedix Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.13.2 RadioMedix Radioimmunotherapy Product Portfolio
- 7.13.3 RadioMedix Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.14 Telix Pharmaceuticals
- 7.14.1 Telix Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.14.2 Telix Pharmaceuticals Radioimmunotherapy Product Portfolio
- 7.14.3 Telix Pharmaceuticals Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.15 Orano Med
- 7.15.1 Orano Med Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.15.2 Orano Med Radioimmunotherapy Product Portfolio
- 7.15.3 Orano Med Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.16 Actinium Pharmaceuticals
- 7.16.1 Actinium Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.16.2 Actinium Pharmaceuticals Radioimmunotherapy Product Portfolio
- 7.16.3 Actinium Pharmaceuticals Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.17 Y-mAbs Therapeutics
- 7.17.1 Y-mAbs Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.17.2 Y-mAbs Therapeutics Radioimmunotherapy Product Portfolio
- 7.17.3 Y-mAbs Therapeutics Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.18 Fusion Pharmaceuticals
- 7.18.1 Fusion Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.18.2 Fusion Pharmaceuticals Radioimmunotherapy Product Portfolio
- 7.18.3 Fusion Pharmaceuticals Radioimmunotherapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Radioimmunotherapy Industry Chain Analysis
- 8.2 Radioimmunotherapy Product Downstream Application Analysis
- 8.2.1 Global Radioimmunotherapy Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global Radioimmunotherapy Revenue and Forecast by Application (2020-2032)
- 8.3 Radioimmunotherapy Typical Downstream Customers
- 8.4 Radioimmunotherapy Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
